에 대한 최신 뉴스 Incyte (NASDAQ:INCY) 주식

INCYTE CORP

Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Meta Platforms Makes AI Moves

Analyst Color

Equities

Government

Market Summary

News

Futures

Economics

Markets

Tech

ETFs

AAPL

DECK

INCY

TMUS

블룸버그 인텔리전스의 수석 주식 전략가이자 주식 전략 글로벌 디렉터인 지나 마틴 아담스가 공유한 데이터는 도널드 트럼프 대통령이 수요일에 발표한 상호관세의 영향을 받을 가능성이 있는 미국 내 상위 기술 기업을 나타낸다.

메타·AMD·애플·AT&amp;T 등 미국 빅테크 기업, 관세로 인한 무역 혼란 속 가장 큰 타격 입을 수도

Xpeng g6 SUV

Large Cap

Movers

BEKE

FUTU

MRNA

RDDT

XPEV

지난주에 가장 저조한 성과를 보인 대형주 10종목은 다음과 같다. KE 홀딩스, 레딧, 인사이트, 제임스 하디, 샤오펑, 뉴코, 부즈 앨런, 텔러스, 푸투, 마이크론

샤오펑·레딧·마이크론 등 지난주 급락한 대형주 (3월 17일~21일)

Why It Matters

Price Target

Analyst Ratings

Trading Ideas

ALGN

GOOGL

LYFT

PENN

TSLA

화요일(18일) 월가의 상위 애널리스트들이 아래 종목에 대한 전망을 변경했다.  모든 애널리스트의 등급 변경 사항은 애널리스트 등급 페이지에서 확인할 수 있다. 아메리칸 익스프레스, 센티넬원, 펜 엔터테인먼트, GE 버노바, 얼라인, 씨게이트, 리프트, 테슬라, 인사이트, 알파벳

월가 상위 애널리스트 의견 변동: 테슬라 목표주가 320달러?

Incyte Corp

Biotech

General

Incyte Announces That FDA Has Extended The Review Period For The Supplemental New Drug Application For Ruxolitinib Cream; The FDA Extended The PDUFA Action Date To Allow Time To Review Additional Chemistry, Manufacturing And Controls Data On The 0.75% Strength Submitted By Incyte In Response To A Recent FDA Information Request

<a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tafasitamab-cxix-relapsed-or-refractory-follicular-lymphoma" title="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tafasitamab-cxix-relapsed-or-refractory-follicular-lymphoma">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tafasitamab-cxix-relapsed-or-refractory-follicular-lymphoma</a>

'FDA Approves Tafasitamab-cxix For Relapsed Or Refractory Follicular Lymphoma' - FDA

Stifel analyst Stephen Willey upgrades Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Hold to Buy and raises the price target from $75 to $107.

Upgrades

Stifel Upgrades Incyte to Buy, Raises Price Target to $107

WIIM

Incyte shares are trading higher after the company announced a collaboration with QIAGEN to develop a novel diagnostic panel to support its portfolio of investigational therapies for patients with myeloproliferative neoplasms. Also, the company announced first clinical data from two studies evaluating the safety, tolerability and efficacy of INCA033989.

Incyte&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) on Sunday revealed the first clinical data from two studies evaluating the safety, tolerability, and efficacy of INCA033989 for mutant calreticulin (mutCALR)-expressing <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">myeloproliferative neoplasms (MPNs)</a>.
MPNs are&nbsp;a group of rare blood cancers where the bone marrow produces too many blood cells (red blood cells, white blood cells, or platelets).
These data, featured at the European Hematology Association 2025 (EHA2025), focus on the dose escalation portion of the&nbsp;studies in patients with high risk essential thrombocythemia (ET) who are resistant/intolerant to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45940099/positive-late-breaking-data-for-incytes-first-in-class-mutcalr-targeted-therapy-inca033989-in-esse" rel="noreferrer noopener">prior cytoreductive therapy</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/03/44356786/incytes-new-treatment-for-chronic-skin-disease-shows-promising-results-in-latest-clinical-trials-stock-falls" target="_blank" rel="noreferrer noopener">Incyte&#8217;s New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls</a>
The studies evaluated the safety and efficacy of INCA033989 in patients with ET as measured by hematologic response and reduction in mutCALR variant allele frequency (VAF).
As of April 4, 2025, results showed rapid and durable normalization of platelet counts across all dose levels, with a trend toward improved responses in higher doses (&gt;400 mg) in patients with ET treated with INCA033989.
Eighty-six percent of patients at doses 400 mg and above achieved a complete or partial hematologic response, with the majority (82%) achieving a complete response.
Eighty-nine percent of evaluable patients (34/38) showed a reduction in mutCALR VAF from baseline. A partial molecular response (>50% VAF reduction) was observed in 21% of evaluable patients (8/38) after only three cycles of treatment.
An exploratory study using single-cell DNA (scDNA) sequencing showed that INCA033989 directly targets and reduces cells carrying mutCALR. This reduction was seen in early blood-forming (CD34-positive) cells and cells in the myeloid-erythroid (ME) lineage.
At the same time, there was an increase in healthy (wild-type CALR) cells, suggesting that the treatment supports the return of normal blood production.
Bone marrow biopsies further confirmed these effects, showing fewer megakaryocytes with mutCALR protein and a notable increase in megakaryocytes without mutCALR protein.
The results (N=49) showed that INCA033989 was well tolerated across all dose cohorts (24 to 2,500 mg), with no dose-limiting toxicities observed.
Additional data from the INCA033989 study in patients with myelofibrosis will be submitted for presentation at a future medical meeting. Discussions with regulatory authorities are planned with the goal to initiate a Phase 3 study by early 2026.
William Blair views the INCA33989 update as promising, with strong initial efficacy reported. However, some questions remain around dosing differences between type 1 and type 2 mutCALR patients and the best setting for the therapy in ET patients (post-hydroxyurea, in combination, or head-to-head).
Analyst Matt Phipps noted that investors have debated the read-through of the ET data to the potential of INCA33989 in MF, where results as a monotherapy and in combination with Jakafi are expected later this year. The VAF reductions are encouraging and likely to have read-through to additional indications, he mentioned in a report.
Price Action: INCY stock is trading higher by 6.82% to $72.37 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45755748/johnson-johnson-highlights-multiple-blood-cancer-trial-data-at-asco-presentation" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation</a></li>
</ul>
Photo via Shutterstock

Health Care

Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses

Shares of Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) rose sharply in today's <a href="https://www.benzinga.com/quote/INCY">pre-market trading</a>.
QIAGEN and Incyte disclosed a precision medicine collaboration to develop companion diagnostics for patients with mutant CALR-expressing Myeloproliferative Neoplasms (MPNs).
Incyte shares jumped 9.6% to $74.25 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>TMD Energy Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMDE#NYSE">TMDE</a>) surged 203% to $3.85 in pre-market trading after gaining over 75% on Friday.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares jumped 169.6% to $43.00 in pre-market trading after dipping 97% on Friday.</li>
<li>Battalion Oil Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BATL#NASDAQ">BATL</a>) jumped 166% to $4.37 in pre-market trading after gaining 15% on Friday.</li>
<li>OceanPal Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) gained 91.9% to $3.09 in pre-market trading after gaining 123% on Friday.</li>
<li>K Wave Media Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWM#NASDAQ">KWM</a>) rose 69.3% to $4.91 in pre-market trading after tumbling over 50% on Friday.</li>
<li>New Era Helium, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEHC#NASDAQ">NEHC</a>) climbed 51.1% to $0.8206 in pre-market trading after declining around 10% on Friday. New Era Helium, last week, announced that its joint venture with Sharon AI, Texas Critical Data Centers, is in active discussions with enterprises to anchor its planned AI infrastructure buildout in Texas.</li>
<li>EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) rose 47.8% to $24.83 in pre-market trading after falling 7% on Friday.</li>
<li>AIRO Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRO#NASDAQ">AIRO</a>) surged 30.2% to $31.25 in pre-market trading after jumping 140% on Friday. AIRO Group priced its $60 million initial public offering of 6 million common shares at $10 per share.</li>
<li>IperionX Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPX#NASDAQ">IPX</a>) gained 13% to $29.31 in pre-market trading after falling 5% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares tumbled 31.4% to $24.86 in pre-market trading after the company suspended ELEVIDYS shipments and paused ENVISION trial after second fatal liver failure in non-ambulatory Duchenne patients.</li>
<li>Dragonfly Energy Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) dipped 26.5% to $0.2228 in pre-market trading after falling 10% on Friday.</li>
<li>KULR Technology Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) shares fell 21.9% to $0.8980 in pre-market trading after the company reported a 1-for-8 reverse stock split.</li>
<li>MicroAlgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) declined 17% to $0.7141 in pre-market trading after dipping 22% on Friday.</li>
<li>Greenlane Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) fell 15.9% to $0.0085 in pre-market trading after tumbling 34% on Friday.</li>
<li>Gold Royalty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROY#NYSE">GROY</a>) dipped 14.7% to $1.95 in pre-market trading. Canaccord Genuity, on June 11, initiated a Buy rating on the stock and announced a $3 price target.</li>
<li>Catheter Precision, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NYSE">VTAK</a>) declined 9.8% to $0.3150 in pre-market trading after dipping 15% on Friday.</li>
<li>Solid Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) fell 8% to $4.15 in pre-market trading. JMP Securities, on June 6, reiterated its Market Outperform rating on the stock and maintained a $15 price target.</li>
<li>FiEE, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) declined 7% to $2.47 in pre-market trading.</li>
<li>Omada Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMDA#NASDAQ">OMDA</a>) fell 5.4% to $16.18 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june">Top 2 Energy Stocks That May Fall Off A Cliff in June</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

AIRO

BATL

DFLI

GNLN

GROY

KULR

MINM

MLGO

NEHC

OMDA

SATS

SLDB

SRPT

TMDE

VTAK

Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

<ul>
<li>QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies</li>
<li>Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs</li>
<li>Panel to be validated on Illumina NextSeq 550Dx platform for use with whole blood samples</li>
<li>Partnership supports Incyte's extensive portfolio in myeloproliferative neoplasms, including INCA033989, and enhances QIAGEN's onco-hematology diagnostics pipeline</li>
</ul>

ILMN

QGEN

Reported Sunday, Incyte Taps QIAGEN And Illumina Technology To Advance Precision Diagnostics For CALR-Driven Myeloproliferative Neoplasms

<ul>
<li>POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy</li>
<li>The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival</li>
<li>In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz&#xAE; (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review</li>
</ul>

Reported Earlier, Incyte's Retifanlimab (Zynyz) Shows Median PFS of 9.3 Months vs 7.4 With Placebo In SCAC Phase 3 Study Published In The Lancet Following May 2025 FDA Approval

Independent biopharmaceutical company&nbsp;Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add further countries in the Asia-Pacific region. The expanded agreement will see new therapies axatilimab (registered as Niktimvo&#xAE; in the United States) and retifanlimab (registered as Zynyz&#xAE; in the U.S. and European Union) added to the current partnered portfolio of Minjuvi&#xAE; (tafasitamab) and Pemazyre&#xAE; (pemigatinib).
Under the terms of the expanded agreement, Incyte will be responsible for the development, manufacture and supply of both axatilimab and retifanlimab to the region, while ST will have responsibility for regulatory, distribution and local marketing and medical affairs related activities.
ST anticipates submitting axatilimab and retifanlimab for local regulatory and reimbursement approval in 2025.
 &nbsp;

Specialised Therapeutics Expands Existing Supply And Distribution Agreement With Incyte Biosciences To Launch, Distribute Two Additional Medicines From Oncology Portfolio In Australia, New Zealand And Singapore

Across the recent three months, 8 analysts have shared their insights on Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $69.62, a high estimate of $92.00, and a low estimate of $59.00. Observing a downward trend, the current average is 0.54% lower than the prior average price target of $70.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1748977277_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Incyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$73.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$59.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$67.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$72.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Incyte. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Incyte compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Incyte's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Incyte's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/INCY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Incyte analyst ratings.</a>
<h2>Get to Know Incyte Better</h2>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>Incyte: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Incyte's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 19.53%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Incyte's net margin excels beyond industry benchmarks, reaching 15.03%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Incyte's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.45%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.83%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Incyte Stands With Analysts

UBS analyst Ashwani Verma maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Neutral and maintains $61 price target.

UBS Maintains Neutral on Incyte, Maintains $61 Price Target

<ul>
<li>Late-breaking oral presentation will highlight new data from a trial of INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody, in patients with essential thrombocythemia (ET)</li>
<li>Incyte to host an in-person analyst and investor event highlighting the mutCALR data at EHA on Sunday, June 15, 2025, from 6:00 - 7:30 a.m. EDT (12:00 - 1:30 p.m. CEST)</li>
</ul>
Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 – 15, 2025, in Milan.
"We're looking forward to presenting new data from across our hematology/oncology portfolio at the 2025 EHA Congress, including late-breaking data for our first in class, mutCALR-directed monoclonal antibody, INCA033989," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "We believe the data that will be presented at the late-breaking session demonstrate the impact of the novel mechanism of action of this monoclonal antibody against mutCALR-driven essential thrombocythemia (ET), and support its potential to be a disease modifying agent and thus transform the treatment of patients with myeloproliferative neoplasms (MPNs) like essential thrombocythemia (ET)."

Incyte To Present New Data From Across Hematology/Oncology Portfolio At 2025 EHA Congress, Including Late-Breaking Data For First In Class, Mutcalr-Directed Monoclonal Antibody, INCA033989

Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Hold and raises the price target from $72 to $73.

Truist Securities Maintains Hold on Incyte, Raises Price Target to $73

<ul>
<li>Zynyz&#xAE; (retifanlimab-dlwr), a PD-1 inhibitor, is now approved for the treatment of advanced squamous cell carcinoma of the anal canal (SCAC) in combination with chemotherapy and as a monotherapy</li>
<li>Patients with SCAC treated with Zynyz achieved a statistically significant improvement in progression-free survival and improvement in overall survival</li>
</ul>
Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz&#xAE; (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, the FDA granted approval for Zynyz as a single agent for the treatment of adult patients with locally recurrent or with metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.

Incyte Announces FDA Approval Of Zynyz Making It First And Only Approved First-Line Treatment For Advanced Anal Cancer Patients In US

On May 11, 2025, Incyte Corporation (the "Company") and Novartis Pharma AG ("Novartis") entered into a settlement agreement (the "Settlement Agreement") with respect to litigation initiated by Novartis and relating to the duration of royalty payments owed by the Company to Novartis under the Collaboration and License Agreement dated November 24, 2009, as amended, between the Company and Novartis. As of March 31, 2025, the Company had approximately $537.1 million of accrued royalties relating to the dispute with Novartis included in accrued and other current liabilities on the Company's condensed consolidated balance sheet. Under the Settlement Agreement, the Company has agreed to pay to Novartis $280.0 million as the settlement of disputed royalties on net sales of JAKAFI in the United States through December 31, 2024, and the parties agreed to reduce by 50% the royalty rate payable by the Company on future net sales of JAKAFI in the United States beginning January 1, 2025 for a period defined in the Settlement Agreement. The reduced royalty payable for the quarter ended March 31, 2025, is approximately $14.9 million. The difference of $242.2 million between the total accrued royalties and the total amount to be paid by the Company to Novartis as disclosed above will be recorded in the Company's condensed consolidated statement of operations for the quarter ending June 30, 2025.

Contracts

Legal

Incyte And Novartis Settle Royalty Dispute With $280M Payment And 50% Reduction In Future JAKAFI U.S. Royalties, Resolving Litigation Over 2009 Collaboration Agreement And Releasing $242.2M In Accrued Liabilities

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $72.89, a high estimate of $92.00, and a low estimate of $59.00. Experiencing a 1.94% decline, the current average is now lower than the previous average price target of $74.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1746050425_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Incyte. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$59.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$67.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$72.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$68.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$77.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Incyte. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Incyte compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Incyte's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Incyte's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/INCY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Incyte analyst ratings.</a>
<h2>Get to Know Incyte Better</h2>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>Key Indicators: Incyte's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Incyte's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 16.32%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Incyte's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 17.07%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Incyte's ROE excels beyond industry benchmarks, reaching 6.08%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Incyte's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.85%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

9 Analysts Have This To Say About Incyte

Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Equal-Weight and raises the price target from $58 to $59.

Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $59

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Sector Perform and raises the price target from $64 to $67.

RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $67

Wall Street rose modestly by midday Tuesday, as investors weighed the latest developments in trade negotiations and awaited a wave of key economic data and corporate earnings set for <a href="https://www.benzinga.com/25/04/45072497/us-trade-deficit-explodes-to-record-162-billion-in-march-as-import-frenzy-precedes-trumps-tariff-barrage">release later this week.</a>
President Donald Trump is <a href="https://apnews.com/article/trump-tariffs-automakers-factories-relief-25a400c98e02c01c8c54502384e267e1">expected</a> to unveil a new executive order on auto tariffs later today. Meanwhile, U.S. Treasury Secretary Bessent added that the administration is pursuing bilateral trade agreements with 17 major partners, excluding China.
The S&amp;P 500 climbed 0.4%, putting it on track for a sixth consecutive gain—its longest winning streak since November 2024.
In the bond market, U.S. Treasuries extended their rally, with yields falling for a sixth straight session. The yield on the 10-year benchmark dropped to 4.17%, marking a two-week low.
Gold prices slipped 0.6% to $3,325 per ounce, while WTI crude oil futures fell 2.4% to $60 per barrel, the lowest level in two weeks. Oil prices are under pressure from escalating global trade tensions and weaker U.S. economic data, and crude is now on track for a 15% decline in April—its steepest monthly drop since 2021.
Bitcoin traded little changed, around $95,000.
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
<td>1-day %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,513.32</td>
<td>+285.73</td>
<td>0.7%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,548.89</td>
<td>+20.14</td>
<td>0.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,468.38</td>
<td>+41.09</td>
<td>0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,969.38</td>
<td>+3.83</td>
<td>0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:40 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.4% up to $552.91.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.7% to $404.9.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;edged 0.3% higher to $473.78.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.5% to $195.96.</li>
<li>The&nbsp;Materials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) outperformed, up 0.8%; the&nbsp;Energy&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.5%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h3>
Stocks moving on earnings report included:
<ul>
<li>Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>): down 0.6%</li>
<li>Cadence Design Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>): up 4.0%</li>
<li>Brown &amp; Brown, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>): down 6.3%</li>
<li>Nucor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>): up 0.9%</li>
<li>F5 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>): down 0.9%</li>
<li>Alexandria Real Estate Equities Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>): down 6.7%</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>): down 1.0%</li>
<li>S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>): up 2.7%</li>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>): up 5.0%</li>
<li>American Tower Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>): up 4.3%</li>
<li>Sherwin-Williams Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>): up 5.2%</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>): down 7.7%</li>
<li>Zebra Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>): up 6.1%</li>
<li>Ecolab, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>): up 2.2%</li>
<li>Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>): up 1.6%</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>): up 2.3%</li>
<li>Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>): down 1.6%</li>
<li>United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>): down 0.5%</li>
<li>General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>): down 0.7%</li>
<li>PayPal Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): up 1.9%</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>): up 4.4%</li>
<li>Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): up 0.8%</li>
<li>Sysco Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>): up 0.4%</li>
<li>Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>): up 1.5%</li>
<li>Incyte Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>): up 1.5%</li>
<li>Altria Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>): up 0.7%</li>
<li>Corning, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>): up 2.5%</li>
<li>Paccar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>): down 3.0%</li>
<li>A.O. Smith Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>): up 4.0%</li>
<li>Kraft Heinz Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>): up 0.5%</li>
<li>Entergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>): down 1.4%</li>
</ul>
Stocks slated to report earnings after the bell include Arch Capital Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>), Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), Mondelez International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>), Caesars Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>), Veralto Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLTO#NYSE">VLTO</a>), Seagate Technology Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>), Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>), Extendicare Inc. (TSE: EXE), Fair Isaac Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Boston Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>), PPG Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>), Extra Space Storage Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>), Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>), ONEOK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>), First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), CoStar Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>), Regency Centers Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REG#NASDAQ">REG</a>), Essex Property Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>), and Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>).
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45074861/us-consumer-expectations-falls-to-13-year-lows-as-recession-fears-inflation-worries-surge">US Consumer Expectations Falls To 13-Year Lows As Recession Fears, Inflation Worries Surge</a></li>
</ul>
Image: Shutterstock

Macro Economic Events

Broad U.S. Equity ETFs

ACGL

BKNG

CDNS

CSGP

SPDR Dow Jones Industrial Average ETF Trust

FFIV

FICO

FSLR

Laboratory Corporation Of America Holdings

MDLZ

PCAR

PYPL

REGN

SBUX

SPGI

VLTO

Select Sector SPDR-Consumer Discretionary

ZBRA

Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What's Driving Markets Tuesday?

INCY stock has given up its prior gain. Incyte shares were trading higher after the company reported better-than-expected Q1 financial results

Press Releases

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

Incyte to Present at Upcoming Investor Conference

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions

Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Caris Life Sciences

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Stifel

Truist Securities

Wells Fargo

RBC Capital

Incyte Pharms

세계화의 최대 수혜자였던 미국의 상위 기술 다국적 기업들이 주목받고 있다. 관세가 이들 기업의 상품 판매 비용에 큰 영향을 미칠 수 있기 때문이다.
무슨 일 있었나: 블룸버그 인텔리전스의 수석 주식 전략가이자 주식 전략 글로벌 디렉터인 지나 마틴 아담스가 공유한 데이터는 도널드 트럼프 대통령이 <a href="https://www.benzinga.com/markets/25/04/44621408/market-access-has-a-price-trump-unveils-list-of-tariffs-countries-targeted" target="_blank" rel="noopener">수요일에 발표한 상호관세</a>의 영향을 받을 가능성이 있는 미국 내 상위 기술 기업을 나타낸다.
이러한 기업들은 "관세가 무역 혼란을 촉발하고 미국 기업의 오랜 마진 우위를 위협하면서 가장 큰 타격을 입을 수 있다.&#8221;
그가 공유한 그래픽에 따르면 <a href="https://www.benzinga.com/news/legal/25/04/44620411/mark-zuckerberg-led-meta-set-to-face-truth-at-senate-hearing-over-china-operations-and-communist-party-censorship-efforts" target="_blank" rel="noopener">마크 저커버그</a>의 메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)는 미국에서 제품 및 서비스를 생산하는 데 필요한 총 금액의 10% 미만을 지출하여 관세에 가장 취약한 것으로 나타났다.
상위 10개 기업에는 AMD(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), AT&amp;T(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>)도 포함된다.
아담스는 이들 기업이 다른 국가의 보복으로 인해 더 많은 어려움에 직면하여 글로벌 공급망에 더 큰 영향을 미칠 수 있다고 말했다. "보복이 글로벌 공급망을 더욱 압박하기 때문에 백악관의 관세는 시작에 불과할 수 있다.&#8221;
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
US multinationals, arguably the biggest driver and beneficiary of globalization, may suffer most as tariffs spark trade turmoil and threaten margin domination of American companies. White House tariffs may only be the start, as retaliations further strain global supply chains. <a href="https://t.co/kbopS2fsT8">pic.twitter.com/kbopS2fsT8</a>
&mdash; Gina Martin Adams (@GinaMartinAdams) <a href="https://twitter.com/GinaMartinAdams/status/1907580802222690759?ref_src=twsrc%5Etfw">April 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
왜 중요한가: 아담스에 따르면, "대중의 믿음과는 달리, 미국의 대형주들은 상당한 위험에 처할 수 있고, 높은 밸류에이션과 마진 해자가 유지될 것이라는 가정이 손상될 수 있다.&#8221;
&#8220;미국 외 지역에서 시설 노출도가 높고 매출원가율이 높은 기업이 단기적으로 가장 큰 직접적인 위협에 직면할 것이며, 매출 노출도가 높은 기업도 자유로울 수 없다.&#8221;
그러나 그는 "미국 기업들이 새로운 체제에 적응하는 과정에서 비국내 주식과 방어적인 미국 부문이 어느 정도 피난처가 될 수 있다"고 덧붙였다.
웨드부시의 댄 아이브스는 "현재로서는 협상만이 백악관의 유일한 선택지"라고 했다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
We would characterize this slate of tariffs as &quot;worse than the worst case scenario&quot; the Street was fearing. The biggest focus will be the China 34% tariff and Taiwan 32% and how this impacts supply chain and demand. Negotiations the only option at this point for White House.
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1907611902047338791?ref_src=twsrc%5Etfw">April 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
반면 베어 트랩 리포트의 크레이그 샤피로는 트럼프가 무역 파트너의 양보를 바라는 것이 아니라 "재정적자 예산 구멍을 메우기 위해 관세 매출을 원하거나 필요로 한다"고 주장한다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
What the market fails to realize is that Trump doesn&#39;t want concessions from trading partners. 
He wants/needs the tariff revenues to help plug the fiscal deficit budget hole <a href="https://t.co/nQf82Q2Zan">https://t.co/nQf82Q2Zan</a>
&mdash; Craig Shapiro (@ces921) <a href="https://twitter.com/ces921/status/1905609335599698141?ref_src=twsrc%5Etfw">March 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
주가 움직임: 아담스가 제시한 관세에 가장 취약한 상위 10개 기업과 주가 움직임은 다음과 같다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>기업</td>
<td>수요일 장 마감 후</td>
<td>연초 대비</td>
<td>1년</td>
</tr>
<tr>
<td>메타 플랫폼스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>-4.83%</td>
<td>-2.55%</td>
<td>15.23%</td>
</tr>
<tr>
<td>데커스 아울도어 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>)</td>
<td>-11.85%</td>
<td>-42.32%</td>
<td>-21.41%</td>
</tr>
<tr>
<td>인사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)</td>
<td>-3.74%</td>
<td>-10.36%</td>
<td>12.69%</td>
</tr>
<tr>
<td>AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</td>
<td>-5.79%</td>
<td>-14.65%</td>
<td>-43.04%</td>
</tr>
<tr>
<td>애플 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>-7.14%</td>
<td>-8.19%</td>
<td>31.97%</td>
</tr>
<tr>
<td>AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>)</td>
<td>-0.64%</td>
<td>23.26%</td>
<td>59.80%</td>
</tr>
<tr>
<td>앨버말 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>-3.32%</td>
<td>-15.23%</td>
<td>-43.94%</td>
</tr>
<tr>
<td>버라이즌 커뮤니케이션스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</td>
<td>0.02%</td>
<td>11.27%</td>
<td>4.44%</td>
</tr>
<tr>
<td>티모바일 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>)</td>
<td>-2.68%</td>
<td>20.51%</td>
<td>62.05%</td>
</tr>
<tr>
<td>베스트 바이 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)</td>
<td>-8.99%</td>
<td>-12.12%</td>
<td>4.51%</td>
</tr>
</tbody>
</table>
</figure>
수요일 관세 발표를 앞두고 S&amp;P 500 지수와 나스닥 100 지수를 각각 추종하는 SPDR S&amp;P 500 ETF 신탁(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)과 인베스코 QQQ 신탁 ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 상승했다. <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">벤징가 프로</a> 데이터에 따르면 SPY는 0.63% 상승한 564.52달러, QQQ는 0.73% 상승한 476.15달러를 기록했다.
하지만 목요일 <a href="https://www.benzinga.com/markets/equities/25/04/44620686/sp-500-nasdaq-futures-plunge-over-3-as-trumps-reciprocal-tariff-plan-hits-market-confidence" target="_blank" rel="noopener">다우존스 지수 선물</a>은 2.25% 하락했고, S&amp;P 500 지수 및 나스닥 100 지수 선물 역시 각각 3.02%, 3.52% 하락했다.
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

메타·AMD·애플·AT&T 등 미국 빅테크 기업, 관세로 인한 무역 혼란 속 가장 큰 타격 입을 수도

지난주에 가장 저조한 성과를 보인 대형주 10종목은 다음과 같다.
<ol>
<li>KE 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>): 주가는 15.38% 하락했다. UBS가 매수에서 중립으로 투자의견을 하향 조정하고 <a href="https://www.benzinga.com/quote/beke/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 24.5달러로 발표</a>한 후였다.</li>
<li>레딧 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>): 주가는 지난주 9.76% 하락했다. 구글이 레딧과의 파트너십 확대를 발표하여 레딧 콘텐츠를 <a href="https://www.benzinga.com//node/44369039" target="_blank" rel="noreferrer noopener">구글 제품 전반에 더 효과적으로 통합</a>할 계획을 발표한 후 잠시 급등했지만 주간 하락했다.</li>
<li>인사이트 코퍼레이션 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>): 주가는 8.75% 하락했다. 이는 포보시티닙(Povorcitinib)의 3상 임상시험 결과가 <a href="https://www.benzinga.com//node/44356786" target="_blank" rel="noreferrer noopener">히드라데니티스 수퍼라티바(Hidradenitis suppurativa) 증상 환자</a>를 대상으로 발표된 후 발생한 일이다. 윌리엄 블레어와 구겐하임이 주식을 하향 조정하였고, 트루이스트 증권은 목표주가를 <a href="https://www.benzinga.com/quote/incy/analyst-ratings" target="_blank" rel="noreferrer noopener">74달러에서 72달러로 하향 조정</a>했다.</li>
<li>제임스 하디 인더스트리 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>): 주가는 8.39% 하락했다.</li>
<li>샤오펑 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>): 주가는 8.13% 하락했다. 이는 회사가 <a href="https://www.benzinga.com//node/44373548" target="_blank" rel="noreferrer noopener">4분기 조정 EPS 실적이 예상치를 밑돌았다</a>고 보고한 후 발생한 일이다.</li>
<li>뉴코 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>): 주가는 7.63% 하락했다. 회사가 1분기 조정 <a href="https://www.benzinga.com//node/44426184" target="_blank" rel="noreferrer noopener">EPS 가이던스를 예상치 이하로 발표</a>한 후 하락했다.</li>
<li>부즈 앨런 해밀턴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>): 주가는 7.22% 하락했다. 회사는 쉴드AI(Shield AI)와의 전략적 파트너십을 통해 <a href="https://www.benzinga.com//node/44378015" target="_blank" rel="noreferrer noopener">미 정부를 위한 AI 기반 자율 솔루션</a>을 제공할 것이라고 발표했다.</li>
<li>텔러스 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TU#NYSE">TU</a>): 주가는 7.07% 하락했다.</li>
<li>푸투 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>): 주가는 7.01% 하락했다. 이는 중국 인민은행이 1년 만기 대출 우대 금리를 3.1%, 5년 만기 금리를 3.6%로 동결했기 때문일 수 있다. 정책 입안자들은 무역 갈등 심화 속에서 위안화를 안정시키면서 경제 성장을 지원하는 방법을 모색하고 있다.</li>
<li>마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>): 주가는 6.02% 하락했다. 이는 로젠블랫이 <a href="https://www.benzinga.com/quote/MU/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 250달러에서 200달러로 하향 조정</a>한 후 발생한 일이다. 회사는 <a href="https://www.benzinga.com//node/44425486" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a>을 발표했다.</li>
</ol>
이미지 제공: Robert Way via Shutterstock
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EB%A1%9C%EB%B9%88%ED%9B%84%EB%93%9C%EB%A1%9C%EC%BF%A0%EC%87%BC%ED%94%BC%ED%8C%8C%EC%9D%B4-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EA%B8%89%EB%93%B1%ED%95%9C-%EB%8C%80%ED%98%95%EC%A3%BC-3/">로빈후드·로쿠·쇼피파이 등 지난주 급등한 대형주 (3월 17일~21일)</a>
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

화요일(18일) 월가의 상위 애널리스트들이 아래 종목에 대한 전망을 변경했다.  모든 애널리스트의 등급 변경 사항은 <a href="https://www.benzinga.com/analyst-stock-ratings" target="_blank" rel="noopener">애널리스트 등급 페이지</a>에서 확인할 수 있다.
<ul>
<li>골드만삭스는 아메리칸 익스프레스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) 목표주가를 367달러에서 330달러로 하향 조정했다. 골드만삭스 애널리스트 라이언 내쉬는 매수 등급을 유지했다. 아메리칸 익스프레스 주식은 월요일에 264.38달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/AXP/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>모건스탠리는 센티넬원(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) 목표주가를 27달러에서 20달러로 대폭 하향 조정했다. 모건스탠리 애널리스트 함자 포더왈라는 중립 등급을 유지했다. 센티넬원 주식은 월요일에 18.91달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/S/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>스티펠은 펜 엔터테인먼트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) 목표주가를 22달러에서 19달러로 하향 조정했다. 스티펠 애널리스트 스티븐 비첸스키는 보유 등급을 유지했다. 펜 엔터테인먼트 주식은 월요일에 17.26달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/PENN/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>RBC 캐피털은 GE 버노바(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) 목표주가를 453달러에서 445달러로 하향 조정했다. RBC 캐피털 애널리스트 크리스토퍼 덴드리노스는 시장수익률 상회 등급을 유지했다. GE 버노바 주식은 월요일에 331.96달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/GEV/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>파이퍼 샌들러는 얼라인 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) 목표주가를 270달러에서 235달러로 하향 조정했다. 파이퍼 샌들러 애널리스트 제이슨 베드나르는 비중확대 등급을 재확인했다. 얼라인 테크놀로지 주식은 월요일에 169.59달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/ALGNX/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>씨티그룹은 씨게이트 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) 목표주가를 125달러에서 115달러로 하향 조정했다. 씨티그룹 애널리스트 아시아 머천트는 매수 등급을 유지했다. 씨게이트 주식은 월요일에 90.51달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/STX/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>루프 캐피털은 리프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) 목표주가를 23달러에서 20달러로 하향 조정했다. 루프 캐피털 애널리스트 롭 샌더슨은 매수 등급을 유지했다. 리프트 주식은 월요일에 12.03달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/LYFT/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>트루이스트 증권은 인사이트 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) 목표주가를 74달러에서 72달러로 하향 조정했다. 트루이스트 증권 애널리스트 스리크리파 데바라콘다는 보유 등급을 유지했다. 인사이트 주식은 월요일에 62.01달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/INCY/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>RBC 캐피털은 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) 목표주가를 440달러에서 320달러로 하향 조정했다. RBC 캐피털 애널리스트 톰 나라얀은 시장수익률 상회 등급을 유지했다. 테슬라 주식은 월요일에 238.01달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
<li>키뱅크는 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) 목표주가를 220달러에서 202달러로 하향 조정했다. 키뱅크 애널리스트 저스틴 패터슨은 비중확대 등급을 유지했다. 알파벳 주식은 월요일에 164.29달러로 마감했다. 다른 애널리스트들이 이 주식을 어떻게 평가하는지 보려면 <a href="https://www.benzinga.com/quote/GOOGL/analyst-ratings" target="_blank" rel="noopener">여기를 클릭하세요.</a></li>
</ul>
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

지난 주 가장 성적이 저조했던 대형주들입니다. 당신의 포트폴리오에 포함되어 있나요?
1. 타깃 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>)의 주식은 회사가 3분기 실적을 발표했으나 예상에 미치지 못하고, 애널리스트들이 <a href="https://www.benzinga.com/node/42117500" target="_blank" rel="noreferrer noopener">주가 목표를 하향 조정</a>한 후 17.83% 하락했다.
2. 테무의 모회사인 PDD 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식은 회사가 <a href="https://www.benzinga.com/node/42111158" target="_blank" rel="noreferrer noopener">예상보다 저조한 재무결과</a>를 발표하고 애널리스트들이 <a href="https://www.benzinga.com/quote/pdd/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 하향 조정</a>한 후 12.22% 급락했다.
3. ZTO 익스프레스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>)의 주식은 회사가 3분기 실적을 발표하고 FY24 <a href="https://www.benzinga.com/node/42076268" target="_blank" rel="noreferrer noopener">소포 물량 가이던스를 하향 조정</a>한 후 8.50% 하락했다.
4. 테넷 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)의 주식은 투자은행 레이먼드 제임스(Raymond James)가 주식을 <a href="https://www.benzinga.com/quote/thc/analyst-ratings" target="_blank" rel="noreferrer noopener">강력 매수에서 아웃퍼폼으로 하향 조정</a>한 후 7.54% 하락했다.
5. 울타 뷰티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>)의 주식은 버크셔 해서웨이가 <a href="https://www.benzinga.com/node/42013172">주식 보유 비중을 축소</a>한 후 7.34% 하락했다.
6. 인튜이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>)의 주식은 회사가 <a href="https://www.benzinga.com/node/42123997" target="_blank" rel="noreferrer noopener">2분기 실적을 발표</a>한 후 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/intu/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 수정</a>하여 6.94% 하락했다.
7. 노키아 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>)의 주식은 회사가 바티 에어텔(<a href="https://www.benzinga.com/node/42089876" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">Bharti Airtel</a>)과 인도에서 수년간 수십억 달러 규모의 계약 연장을 확보했다고 발표한 후 6.28% 하락했다.
8. 알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)의 주식은 회사가 자본을 조달하고 기존 부채를 상환하며 <a href="https://www.benzinga.com/node/42032495" target="_blank" rel="noreferrer noopener">진행 중인 자사주 매입 프로그램</a>을 지원하기 위해 미국 달러 및 중국 위안화 채권을 발행할 계획이라고 발표한 후 6.16% 하락했다.
9. 방코 산탄데르(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>)의 주식은 5.60% 하락했다.
10. 인사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)의 주식은 회사가 MRGPRX4 (INCB000547)에 대한 2상 연구 데이터를 발표하고 <a href="https://www.benzinga.com/node/42070590" target="_blank" rel="noreferrer noopener">추가 개발을 지원하지 않는다고 발표</a>한 후 5.47% 하락했다.
사진 출처: Shutterstock
다음 읽기: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EB%B0%8F-%EC%8B%AC%EB%B3%B4%ED%8B%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10/" target="_blank" rel="noopener">슈퍼 마이크로 및 심보틱 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 18일 – 11월 22일)</a>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

BABA

INTU

ULTA

타깃, 알리바바 및 테무는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (11월 18일 ~ 11월 22일)

기술주가 <a href="https://www.benzinga.com/tech" target="_blank" rel="noopener" data-google-interstitial="false">시장 상승세를 주도함</a>에 따라 나스닥 100 지수는 목요일에 4일 연속 올랐다. 이 지수는 0.6% 오른 19,576포인트로 마감하며 사상 최고치를 경신했다.
S&amp;P 500 지수도 4일 연속 올랐다. 목요일 이 지수는 0.2% 상승해 사상 최고치인 5,433포인트를 기록했다. <a href="https://www.benzinga.com/markets/equities/24/06/39310762/producer-inflation-rise-less-than-expected-jobless-claims-soar-thursdays-economic-digest" target="_blank" rel="noopener" data-google-interstitial="false">실망스러운 실업 수당 청구 데이터</a>로 인한 오전 하락세에서 반등했다.
오후에는 재닛 옐런 미국 재무장관이 디스인플레이션의 지속적인 진전에 대해 낙관론을 표명한 후 트레이더들이 위험 자산에 대한 신뢰를 회복했다. 옐런은 노동시장 압박 완화를 언급하면서도 고용시장은 여전히 ​​강세를 유지하고 있다고 강조했다.
시장은 9월 금리 인하 가능성이 70%에 가까울 것으로 예상하고 있으며, 현재 연말까지 50bp(베이시스포인트) 이상의 인하를 책정하고 있다. 이는 두번의 금리 인하에 해당한다.
S&amp;P 500의 11개 부문 중 목요일 실적에서는 기술 부문이 1% 상승했고 그 뒤를 이어 부동산 부문이 0.5% 상승했다. 두 가지 모두 금리 인하에 대한 기대가 높아지면서 뒷받침되었다.
에너지 부문은 0.9% 감소해 가장 큰 부진을 겪었고, 통신 서비스 부문이 0.7% 감소해 그 뒤를 이었다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>섹터</th>
<th>1일 변동률</th>
</tr>
</thead>
<tbody>
<tr>
<td>기술을 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>1.02%</td>
</tr>
<tr>
<td>부동산을 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>0.52%</td>
</tr>
<tr>
<td>유틸리티를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>0.19%</td>
</tr>
<tr>
<td>소비자 선택 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>0.13%</td>
</tr>
<tr>
<td>기본소비재를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>0.12%</td>
</tr>
<tr>
<td>소재를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>-0.03%</td>
</tr>
<tr>
<td>헬스케어를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>-0.04%</td>
</tr>
<tr>
<td>파이낸셜 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>-0.10%</td>
</tr>
<tr>
<td>산업을 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>-0.64%</td>
</tr>
<tr>
<td>통신 서비스를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>-0.73%</td>
</tr>
<tr>
<td>에너지를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>-0.93%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">나스닥 100의 상승종 5</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>이름</td>
<td>최신</td>
<td>변동률 %</td>
</tr>
<tr>
<td>브로드컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>1,679.29</td>
<td>12.29%</td>
</tr>
<tr>
<td>엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>129.37</td>
<td>3.33%</td>
</tr>
<tr>
<td>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>182.33</td>
<td>2.84%</td>
</tr>
<tr>
<td>엑셀론 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>)</td>
<td>35.40</td>
<td>1.86%</td>
</tr>
<tr>
<td>마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)</td>
<td>143.08</td>
<td>1.66%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">나스닥 100 하락종 상위 5</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>이름</td>
<td>최신</td>
<td>변동률 %</td>
</tr>
<tr>
<td>워너 브라더스 디스커버리 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)</td>
<td>7.31</td>
<td>-6.40%</td>
</tr>
<tr>
<td>몽고DB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>)</td>
<td>218.14</td>
<td>-4.85%</td>
</tr>
<tr>
<td>아틀라시안 코퍼레이션 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>)</td>
<td>156.04</td>
<td>-4.17%</td>
</tr>
<tr>
<td>Z스케일러 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>)</td>
<td>181.00</td>
<td>-4.15%</td>
</tr>
<tr>
<td>시리우스 XM 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>)</td>
<td>2.53</td>
<td>-3.93%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500 상승종 상위 5</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>이름</td>
<td>최신</td>
<td>변동률 %</td>
</tr>
<tr>
<td>수퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)</td>
<td>871.16</td>
<td>12.45%</td>
</tr>
<tr>
<td>브로드컴</td>
<td>1,678.90</td>
<td>12.26%</td>
</tr>
<tr>
<td>아리스타 네트웍스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NASDAQ">ANET</a>)</td>
<td>331.67</td>
<td>6.53%</td>
</tr>
<tr>
<td>인사이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)</td>
<td>62.68</td>
<td>4.57%</td>
</tr>
<tr>
<td>코보 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>)</td>
<td>113.36</td>
<td>4.27%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500 하락종 상위 5</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>이름</td>
<td>최신</td>
<td>변동률 %</td>
</tr>
<tr>
<td>파라마운트 글로벌 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)</td>
<td>10.35</td>
<td>-6.92%</td>
</tr>
<tr>
<td>워너 브라더스 디스커버리</td>
<td>7.31</td>
<td>-6.40%</td>
</tr>
<tr>
<td>엣시 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>)</td>
<td>60.15</td>
<td>-4.93%</td>
</tr>
<tr>
<td>제네락 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>)</td>
<td>136.17</td>
<td>-4.58%</td>
</tr>
<tr>
<td>앨버말 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>108.23</td>
<td>-3.92%</td>
</tr>
</tbody>
</table>
</figure>
지금 읽기: <a href="https://www.benzinga.com/etfs/specialty-etfs/24/06/39317123/goldman-sachs-reaffirms-september-rate-cut-forecast-downplays-feds-hawkish-surprise">골드만삭스, 9월 금리인하 전망 재확인, 연준의 &#8216;매파적 서프라이즈&#8217; 경시</a>
이미지: 셔터스톡

Macro Notification

Mid Cap

Small Cap

ANET

AVGO

ETSY

GNRC

NVDA

PARA

QRVO

SIRI

SMCI

TEAM

나스닥 100, S&P 500은 기술주가 우위를 되찾으며 사상 최고치로 마감: 상승주와 하락주

Comments

Incyte

뉴스

에 대한 최신 뉴스 Incyte (NASDAQ:INCY) 주식

목요일, 4월 03, 2025

일요일, 3월 23, 2025

수요일, 3월 19, 2025

일요일, 11월 24, 2024

목요일, 6월 13, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌